University of Florida reports preclinical success for mRNA melanoma vaccine

Researchers have demonstrated an mRNA-based vaccine capable of activating immune responses against treatment-resistant melanoma in preclinical models. While the findings represent a potential therapeutic advancement, the technology remains in early-stage development and has not yet undergone human clinical trials.